Indian pharmaceutical companies face global scrutiny due to poor performance. Intas Pharmaceuticals, a major player producing cancer drugs for the US, saw a decline in quality.
This has led to a shift in US reliance on India for medicines, with regulatory issues being a primary concern.
Global #scrutiny reveals concerning decline in quality of #Indian pharmaceutical companies.
— SAMAA TV (@SAMAATV) March 26, 2024
Recent reports expose issues with #Intas, impacting #cancer drug production for the #US.
Poor regulatory oversight and data integrity concerns pose risks to patients. #SamaaTV pic.twitter.com/67KDjwuSRG
According to Nikkei Asia, Analog practices and data integrity problems have resulted in tragic deaths, particularly among children.
American doctors warn of potential fatalities due to shortages of cancer drugs, prompting Washington to turn to China for solutions.
During a US Food and Drug Administration inspection of an Indian pharmaceutical factory, significant concerns arose. Manipulated data at Intas prompted FDA to declare their drug adulterated, causing a critical shortage in the US.
Over the past decade, FDA has blocked several Indian pharmaceutical firms for quality control lapses, including Dr. Reddy's Laboratories.
FDA's investigation in western India uncovered flawed strategies among Indian pharmaceutical companies.
